195 related articles for article (PubMed ID: 20357493)
21. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
23. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
[TBL] [Abstract][Full Text] [Related]
24. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
[TBL] [Abstract][Full Text] [Related]
25. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
26. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
27. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
29. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
Franssen R; Sankatsing RR; Hassink E; Hutten B; Ackermans MT; Brinkman K; Oesterholt R; Arenas-Pinto A; Storfer SP; Kastelein JJ; Sauerwein HP; Reiss P; Stroes ES
Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1336-41. PubMed ID: 19667106
[TBL] [Abstract][Full Text] [Related]
30. Prospective observation for seven-year's highly active antiretroviral therapy in Chinese HIV-1 infected patients.
He M; Zheng YH; Zhou HY; Mamadou D; Chen Z; Chen X; Yao YH; He Y
Curr HIV Res; 2011 Apr; 9(3):160-5. PubMed ID: 21585332
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
Palladino C; Briz V; Policarpo SN; Silveira LF; de José MI; González-Tomé MI; Moreno D; León Leal JA; Mellado MJ; de Ory SJ; Ramos JT; Muñoz-Fernández MA
Pediatr Infect Dis J; 2010 Jun; 29(6):563-6. PubMed ID: 20160659
[TBL] [Abstract][Full Text] [Related]
32. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
Pujades-Rodríguez M; Schramm B; Som L; Nerrienet E; Narom P; Chanchhaya N; Ferradini L; Balkan S
Trop Med Int Health; 2011 Feb; 16(2):205-13. PubMed ID: 21087376
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Manosuthi W; Tantanathip P; Chimsuntorn S; Eampokarap B; Thongyen S; Nilkamhang S; Sungkanuparph S
Int J Infect Dis; 2010 Nov; 14(11):e1013-7. PubMed ID: 20880733
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.
Zhou HY; Zheng YH; Zhang CY; Chen J; He Y; Ding PP; Li H
Viral Immunol; 2007; 20(1):180-7. PubMed ID: 17425432
[TBL] [Abstract][Full Text] [Related]
35. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
Bonjoch A; Paredes R; Domingo P; Cervantes M; Pedrol E; Ribera E; Force L; Llibre JM; Vilaró J; Dalmau D; Cucurull J; Mascaró J; Masabeu A; Pérez-Alvarez N; Puig J; Cinquegrana D; Clotet B
AIDS Res Hum Retroviruses; 2006 Apr; 22(4):321-9. PubMed ID: 16623634
[TBL] [Abstract][Full Text] [Related]
37. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
Blanckenberg DH; Wood R; Horban A; Beniowski M; Boron-Kaczmarska A; Trocha H; Halota W; Schmidt RE; Fatkenheuer G; Jessen H; Lange JM;
AIDS; 2004 Mar; 18(4):631-40. PubMed ID: 15090768
[TBL] [Abstract][Full Text] [Related]
39. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
[TBL] [Abstract][Full Text] [Related]
40. Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients.
Reliquet V; Allavena C; Morineau-Le Houssine P; Mounoury O; Raffi F
HIV Clin Trials; 2010; 11(2):110-7. PubMed ID: 20542847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
